Literature DB >> 10395838

In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus.

M Fernández1, J A Quiroga, J Martín, M Herrero, M Pardo, M A Horisberger, V Carreño.   

Abstract

To test whether (HCV) persistence is related to interferon (IFN) hyporesponsiveness, peripheral blood monuclear cells from 29 patients and 11 controls were studied for MxA protein expression. In vitro, only IFN-alpha (P<.001) and interleukin-2 (P<.05) induced MxA protein expression above unstimulated levels. Forty patients were treated with IFN-alpha2b. Patients showed higher basal levels of MxA protein (P<.02) and 2',5'-oligoadenylate synthase (2-5A) activity (P<.05) than controls. During therapy, MxA protein levels (P<.001) and 2-5A activity (P<.05) increased; after 1 month, MxA levels remained high, whereas 2-5A activity declined to initial levels. Increases in MxA were inversely correlated with decreases in serum alanine aminotransferase levels, and MxA induction was greater among virological responders. Thus, the IFN system seems to be activated in chronic HCV infection, but HCV appears to modulate these two components of the IFN system differentially. These results suggest that an inefficient response may contribute to virus persistence and affect the therapeutic outcome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395838     DOI: 10.1086/314859

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Expression of biomarkers of interferon type I in patients suffering from chronic diseases.

Authors:  C Scagnolari; F Bellomi; S Trombetti; M Casato; M Carlesimo; F Bagnato; V Lavolpe; R Bruno; E Millefiorini; L Antonelli; E Girardi; O Turriziani; G Antonelli
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection.

Authors:  Kiminori Uka; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

3.  Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Romy B Christmann; Everett Hayes; Sarah Pendergrass; Cristina Padilla; Giuseppina Farina; Alsya J Affandi; Michael L Whitfield; Harrison W Farber; Robert Lafyatis
Journal:  Arthritis Rheum       Date:  2011-06

4.  Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees.

Authors:  Catherine B Bigger; Bernadette Guerra; Kathleen M Brasky; Gene Hubbard; Michael R Beard; Bruce A Luxon; Stanley M Lemon; Robert E Lanford
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha.

Authors:  Carolina Scagnolari; Pompea Zingariello; Jacopo Vecchiet; Carla Selvaggi; Delia Racciatti; Gloria Taliani; Elisabetta Riva; Eligio Pizzigallo; Guido Antonelli
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

Review 6.  Role of viral and host factors in interferon based therapy of hepatitis C virus infection.

Authors:  Muhammad Imran; Sobia Manzoor; Javed Ashraf; Madiha Khalid; Muqddas Tariq; Hafiza Madeha Khaliq; Sikandar Azam
Journal:  Virol J       Date:  2013-10-01       Impact factor: 4.099

7.  Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study.

Authors:  Mónica García-Álvarez; Juan Berenguer; María A Jiménez-Sousa; Daniel Pineda-Tenor; Teresa Aldámiz-Echevarria; Francisco Tejerina; Cristina Diez; Sonia Vázquez-Morón; Salvador Resino
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

8.  Activation of the interferon-inducible 2'-5'-oligoadenylate synthetase gene by hepatitis C virus core protein.

Authors:  A Naganuma; A Nozaki; T Tanaka; K Sugiyama; H Takagi; M Mori; K Shimotohno; N Kato
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 9.  Interferon-inducible antiviral effectors.

Authors:  Anthony J Sadler; Bryan R G Williams
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

10.  Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B.

Authors:  Ana Luiza Dias Angelo; Lourianne Nascimento Cavalcante; Kiyoko Abe-Sandes; Taísa Bonfim Machado; Denise Carneiro Lemaire; Fernanda Malta; João Renato Pinho; Luiz Guilherme Costa Lyra; Andre Castro Lyra
Journal:  Clinics (Sao Paulo)       Date:  2013-10       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.